111 related articles for article (PubMed ID: 22316567)
1. Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial.
Levine SZ; Rabinowitz J; Faries D; Lawson AH; Ascher-Svanum H
Schizophr Res; 2012 May; 137(1-3):141-6. PubMed ID: 22316567
[TBL] [Abstract][Full Text] [Related]
2. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials.
Stauffer V; Case M; Kollack-Walker S; Ascher-Svanum H; Ball T; Kapur S; Kinon BJ
Schizophr Res; 2011 Aug; 130(1-3):11-9. PubMed ID: 21489754
[TBL] [Abstract][Full Text] [Related]
3. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study.
Levine SZ; Rabinowitz J; Ascher-Svanum H; Faries DE; Lawson AH
Schizophr Res; 2011 Dec; 133(1-3):42-6. PubMed ID: 22000938
[TBL] [Abstract][Full Text] [Related]
4. Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study.
Levine SZ; Rabinowitz J; Case M; Ascher-Svanum H
J Clin Psychopharmacol; 2010 Aug; 30(4):446-9. PubMed ID: 20631562
[TBL] [Abstract][Full Text] [Related]
5. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories.
Levine SZ; Leucht S
Biol Psychiatry; 2010 Jul; 68(1):86-92. PubMed ID: 20227681
[TBL] [Abstract][Full Text] [Related]
6. Placebo response trajectories in short-term and long-term antipsychotic trials in schizophrenia.
Potkin S; Agid O; Siu C; Watsky E; Vanderburg D; Remington G
Schizophr Res; 2011 Nov; 132(2-3):108-13. PubMed ID: 21873032
[TBL] [Abstract][Full Text] [Related]
7. Trajectories and antecedents of treatment response over time in early-episode psychosis.
Levine SZ; Rabinowitz J
Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
[TBL] [Abstract][Full Text] [Related]
8. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials.
Levine SZ; Leucht S
Schizophr Res; 2014 Jun; 156(1):107-14. PubMed ID: 24794879
[TBL] [Abstract][Full Text] [Related]
9. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
10. Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study.
Fervaha G; Agid O; Takeuchi H; Foussias G; Remington G
Eur Neuropsychopharmacol; 2014 Jul; 24(7):1078-85. PubMed ID: 24726579
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
12. Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial.
Perlick DA; Rosenheck RA; Kaczynski R; Swartz MS; Canive JM; Lieberman JA
Schizophr Res; 2010 Feb; 116(2-3):118-25. PubMed ID: 19864114
[TBL] [Abstract][Full Text] [Related]
13. Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia.
Levine SZ; Goldberg Y; Samara M; Davis JM; Leucht S
Schizophr Res; 2015 May; 164(1-3):122-6. PubMed ID: 25790904
[TBL] [Abstract][Full Text] [Related]
14. Early symptom response to antipsychotic medication as a marker of subsequent symptom change: an eighteen-month follow-up study of recent episode schizophrenia.
Levine SZ; Leucht S
Schizophr Res; 2012 Nov; 141(2-3):168-72. PubMed ID: 22995933
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
[TBL] [Abstract][Full Text] [Related]
16. Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data.
Takeuchi H; Fervaha G; Uchida H; Suzuki T; Bies RR; Grönte D; Remington G
J Clin Psychiatry; 2014 May; 75(5):506-11. PubMed ID: 24569099
[TBL] [Abstract][Full Text] [Related]
17. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
18. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
19. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.
Addington DE; Mohamed S; Rosenheck RA; Davis SM; Stroup TS; McEvoy JP; Swartz MS; Lieberman JA
J Clin Psychiatry; 2011 Jan; 72(1):75-80. PubMed ID: 20868641
[TBL] [Abstract][Full Text] [Related]
20. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?
Citrome L; Stroup TS
Int J Clin Pract; 2006 Aug; 60(8):933-40. PubMed ID: 16893436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
